Loading
In a head-to-head trial, the PD-1 antibody pembrolizumab kept relapsed Hodgkin lymphoma at bay for longer than brentuximab vedotin, making immunotherapy the preferred choice after transplant failure or for patients who cannot have a transplant.
International randomised open-label phase 3 trial of 304 patients with relapsed or refractory classical Hodgkin lymphoma after autologous transplant or ineligible for it, assigned to pembrolizumab or brentuximab vedotin.
At the interim analysis median progression-free survival was 13.2 months with pembrolizumab against 8.3 months with brentuximab vedotin (hazard ratio 0.65), with benefit across subgroups including those with primary refractory disease; pneumonitis was more frequent with pembrolizumab and neuropathy with brentuximab vedotin.
PD-1 blockade is the standard for classical Hodgkin lymphoma that has relapsed after or is unsuitable for autologous transplant, ahead of brentuximab vedotin in most patients.
Shares Brentuximab vedotin, Relapsed and refractory classical Hodgkin lymphoma.
Shares The Lancet Oncology, Pembrolizumab.
Shares The Lancet Oncology, Pembrolizumab.
Shares The Lancet Oncology, Pembrolizumab.
Shares The Lancet Oncology, Pembrolizumab.
Shares Brentuximab vedotin, Relapsed and refractory classical Hodgkin lymphoma.
Shares Brentuximab vedotin, Relapsed and refractory classical Hodgkin lymphoma.
Shares Brentuximab vedotin, Pembrolizumab.